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Abstract
Background: Currently used biomarkers for cardiac ischemia are elevated in blood plasma after a delay
of several hours and therefore unable to detect acute coronary syndrome (ACS) in a very early stage.
General practitioners (GPs), however, are often confronted with patients suspected of ACS within hours
after onset of complaints. This ongoing study aims to evaluate the added diagnostic value beyond clinical
assessment for a rapid bedside test for heart-type fatty-acid binding protein (H-FABP), a biomarker that is
detectable as soon as one hour after onset of ischemia.
Methods: Participating GPs perform a blinded H-FABP rapid bedside test (Cardiodetect®) in patients with
symptoms suggestive of ACS such as chest pain or discomfort at rest. All patients, whether referred to
hospital or not, undergo electrocardiography (ECG) and venapunction for a plasma troponin test within
12–36 hours after onset of complaints. A final diagnosis will be established by an expert panel consisting
of two cardiologists and one general practitioner (blinded to the H-FABP test result), using all available
patient information, also including signs and symptoms. The added diagnostic value of the H-FABP test
beyond history taking and physical examination will be determined with receiver operating characteristic
curves derived from multivariate regression analysis.
Conclusion: Reasons for presenting the design of our study include the prevention of publication bias and
unacknowledged alterations in the study aim, design or data-analysis. To our knowledge this study is the
first to assess the diagnostic value of H-FABP outside a hospital-setting. Several previous hospital-based
studies showed the potential value of H-FABP in diagnosing ACS. Up to now however it is unclear whether
these results are equally promising when the test is used in primary care. The first results are expected in
the end of 2008.
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Background
For a general practitioner (GP), diagnosing or excluding
acute coronary syndrome (ACS; comprising unstable
angina (UA) and acute myocardial infarction (AMI))
often poses a diagnostic dilemma. On the one hand, miss-
ing an ACS may lead to excess morbidity and mortality
that could have been prevented with optimal treatment.
Guidelines therefore recommend immediate hospital
referral in patients suspected of ACS, even when suspicion
is relatively low [1,2]. On the other hand, unjustified
referral of patients without ACS increases workload in the
emergency department and causes unnecessary anxiety in
both patients and their relatives. Consequently, adequate
diagnostic assessment, correctly identifying ACS patients,
while limiting unnecessary referral of non-ACS patients is
desirable, but may be difficult to achieve.
Although some patients with chest pain or other symp-
toms suggestive of ACS will contact emergency services
directly, the majority of patients will consult a GP first.
Typically, the GP will assess these patients using history
taking and physical examination only. With these limited
tools it is notoriously difficult to accurately rule out or
rule in ACS, notably in women and elderly patients in
whom signs and symptoms of ACS can be rather atypical
[3]. An electrocardiogram (ECG) may provide additional
diagnostic information in the assessment of ACS, but is
often not available in primary care. Moreover, the initial
ECG of a patient with AMI does not always reveal ST-seg-
ment elevation or Q-wave changes, indicative of infarc-
tion [1]. Alternatively, biomarkers of myocardial damage
could be useful as these, after their appearance in plasma,
show 100% sensitivity. Currently, troponin is the biomar-
ker of choice according to European and American guide-
lines on myocardial infarction. Unfortunately, troponin is
elevated only 6–9 hours after onset of ischemia [1,4,5],
while most patients with symptoms suggestive of ACS
present themselves to the GP between 1 and 3 hours after
symptom onset [6-8]; hours before troponin can be used
to accurately exclude or confirm AMI.
Recent studies in laboratories and the emergency depart-
ment have shown that heart-type fatty acid-binding pro-
tein (H-FABP), a more recently developed cardiac
biomarker, is able to detect myocardial damage as soon as
one hour after onset of ischemia and, therefore, is
regarded the earliest plasma marker available [9-11]. A
bedside test for H-FABP, providing results within 15 min-
utes [12], could potentially reduce diagnostic uncertainty
for patients suspected of ACS in primary care. We there-
fore sought to determine the diagnostic accuracy and fea-
sibility of a rapid bedside test for H-FABP in patients
suspected of ACS in primary care.
Objectives
This study aims to assess the diagnostic value of a rapid
bedside test for H-FABP, in addition to history taking and
physical examination in primary care patients suspected
of ACS. In addition, the balance between costs and effects
of applying the H-FABP bedside test in primary care will
be evaluated.
Methods
Study design and data collection
The study design is depicted in figure 1. Patients are pri-
marily recruited by GPs working at one of three participat-
ing out-of-hours GP services in the region of Utrecht, The
Netherlands (1 urban and 2 semi-urban). Additionally,
25 GPs from group practices will recruit patients during
daytime hours. Diagnostic assessment during the initial
GP consultation includes standardised history taking and
physical examination and rapid H-FABP testing (see
below). To allow for a definitive decision whether ACS is
present ("gold" or reference standard) an ECG is recorded
and a venous blood sample is collected in all patients (for
measurement of currently preferred biomarkers including
troponin, creatinin kinase (CK) and creatinin kinase-
myocardial band (CK-MB)), irrespective of whether or not
they are referred to hospital. In patients who are referred
to hospital these measurements are performed as part of
routine care. Patients who are not referred to hospital are
visited at home by qualified GP laboratory service person-
nel to perform the above mentioned tests. Blood samples
are obtained between 12 to 36 hours after onset of com-
plaints in order to allow for a definitive diagnosis of AMI.
Using this time interval we adopt a safe margin for a tro-
ponin rise to become detectable in the blood.
The study protocol was approved by the Medical Ethics
Committee of the University Medical Center Utrecht, The
Netherlands.
In- and exclusion criteria
All patients with symptoms suggestive of ACS who present
themselves to a GP are eligible for inclusion in the study.
Presenting symptoms will typically include chest pain or
discomfort at rest, but also atypical "vague" complaints
such as abdominal discomfort, dizziness or sudden onset
of dyspnoea.
Excluded are patients with complaints lasting more than
24 hours, as H-FABP levels usually return to normal 24–
36 hours after onset of myocardial ischemia [9,11]. Also
excluded are patients who require instant hospital referral
and those patients in whom no written informed consent
is obtained.BMC Cardiovascular Disorders 2008, 8:8 http://www.biomedcentral.com/1471-2261/8/8
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H-FABP test and clinical score
The H-FABP bedside test (Cardiodetect®  Rennesens
GmbH, Berlin) can easily be performed by the GP by
drawing four drops of capillary whole blood from the
patient's finger and applying them onto the test-strip.
Within 15 minutes the H-FABP test result (elevated or
non-elevated plasma FABP) is available. For study pur-
poses the result is concealed by a blinding-strip. The test is
de-blinded by the GP after he/she has made the referral
decision. Test results are documented on a standardized
case record form, together with findings from history tak-
ing and physical examination. Other items on the form
include age, gender, prior AMI and treatment for AMI
(bypass surgery or percutaneous coronary intervention).
Also recorded are patient delay and doctor delay and a
probability estimate by the GPs (prior to the H-FABP test
result) that a patient has ACS, their decision about referral
to hospital and the result of the H-FABP test.
A previous study by Grijseels et al provided a pre-hospital
decision rule based on items from history taking and
physical examination for patients suspected of ACS [13].
We will validate the diagnostic accuracy of this clinical
score and estimate the added value of the H-FABP bedside
test.
Outcome
An expert panel consisting of two cardiologists and one
GP will establish the final diagnosis using all available
patient information, including signs and symptoms, ECG
and biomarker levels (troponin-T or -I, CK and CK-MB).
These results are available for all patients, including
patients that are not referred to hospital, as they are visited
at home by qualified GP laboratory personnel for per-
formance of ECG and laboratory tests.
AMI will be defined in accordance with guidelines from
the European Society of Cardiology and the American
College of Cardiology [1,5] The diagnosis of AMI is estab-
lished when patients have suggestive symptoms (such as
chest pain) and a maximal concentration of troponin T or
I exceeding the decision limit (99th percentile of the values
for a reference control group) within the first 36 hours
after the onset of complaints and/or CK-MB values greater
than two times the upper reference limit on at least one
occasion during the same time frame. The presence of ST-
and T-wave changes on the ECG, notably ST elevations
and Q-waves, can further confirm AMI. Unstable angina
(UA) is defined as symptoms of chest pain and ST- and/or
T-wave changes on the ECG suggestive of ischemia, with-
out elevation of troponin or CK-MB above the decision
limits [1,5].
Patient management
As already mentioned, every GP will decide about referral
to hospital in accordance with daily practice, using only
history taking and physical examination and, when avail-
able, ECG. This decision is made without using the H-
FABP test result. For safety reasons an exception is made
for patients with a positive H-FABP test result in whom the
GP initially decided not to refer. In these cases, the GP is
instructed to change his initial management decision in
favor of hospital referral.
Flow diagram of study design Figure 1
Flow diagram of study design. Abbreviations: GP = gen-
eral practitioner, ACS = acute coronary syndrome, H-FABP 
= heart-type fatty acid-binding protein, ECG = electrocardio-
gram. * The clinical score is based on ref. 13. ** Measure-
ments are performed by qualified GP laboratory personnel.
300 patients with symptoms suggestive 
of ACS presenting to GP 
Emergency department / 
coronary care unit 
  - ECG recording 
 - Venous blood sampling
Primary care consultation 
• H-FABP rapid test 
• Clinical assessment*:
- history taking 
- physical examination 
- ECG (when available) 
• Patient management  decision 
   (independent of H-FABP test result) 
Patients home** 
  - ECG recording  
  - Venous blood sampling 
 Complementary data collection 
(retrieved from)
- 1month follow-up (GP) 
- Medications, medical history and   
  hospital discharge letter (GP or  
  hospital medical record)
Catchment population 
Patients in the GP out-of-hours area or 
patients enlisted within the participating 
GP-group practices
Expert panel outcome meeting 
(2 cardiologists, 1 GP) 
Using all available information, except 
H-FABP test resultBMC Cardiovascular Disorders 2008, 8:8 http://www.biomedcentral.com/1471-2261/8/8
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Statistical analyses
Using 2 by 2 tables the diagnostic value of the H-FABP test
alone and in combination with the clinical score will be
assessed, using AMI as the outcome, and positive and neg-
ative predictive values, sensitivity and specificity will be
calculated with 95% confidence interval.
Multivariable regression analysis with receiver operating
characteristic (ROC) curves will be used to determine
whether the H-FABP test provides added diagnostic value
beyond history taking and physical examination (summa-
rized in a clinical score). Two diagnostic models will be
tested: one using only the clinical score, the other one
consisting of the clinical score together with the H-FABP
test result. This will lead to 2 different areas under the
ROC-curve (AUC), where the difference in AUC presents
the added value of the H-FABP test.
As AMI is notoriously difficult to diagnose in women and
the elderly we will perform subgroup analyses in these
specific patient categories [1].
Sample size and power calculation
A frequently used 'rule of thumb' recommends that for
each diagnostic determinant included in a multivariable
logistic regression analysis at least 10 events (in this case
AMI) are necessary [15,16]. Our study includes 2 diagnos-
tic determinants (clinical score and H-FABP test result).
Thus, a population in which at least 20 patients with AMI
is required. Although available estimates vary, Dutch
studies show that in more than 10% of patients suspected
of AMI by the GP the diagnosis is confirmed [2,13]. There-
fore, 200 patients with suspected AMI need to be included




In diagnostic prediction research the physician ideally
should be blinded to the results of the test under study in
order to prevent bias in the ascertainment of the disease.
In this study, the H-FABP test result may influence the
inferences drawn from medical history and physical
examination, and thereby influence the referral decision
of the GP, especially since it is notoriously difficult to
decide about the presence or absence of an ACS based on
clinical assessment only.
There are however two important reasons why a fully
blinded H-FABP test is not feasible in our study. Firstly,
previous hospital based studies showed that the H-FABP
bedside test has a positive predictive value of well above
80% [17-20]. We therefore instructed the GPs to decide
on the referral before de-blinding the test result, but for
safety reasons we also instructed them to refer patients
with a positive H-FABP test result to hospital irrespective
of their initial referral decision. Secondly, in the hours fol-
lowing application of the test, discoloration of the test-
strip occurs which negatively influences the interpretation
and thereby the accuracy of the test results. Therefore the
test has to be read shortly after its performance.
Informed consent
It is neither very realistic nor feasible to ask written
informed consent to study participation from a patient in
an acute life threatening situation, such as with symptoms
suggestive for ACS. Therefore the Medical Ethics Commit-
tee agreed to ask verbal consent from patients for taking
the H-FABP test by the GP. Subsequently patients are
given the opportunity for written informed consent after
having read an information letter at a more convenient
moment. Patients may also decide to withdraw their con-
sent then or at any time thereafter. Only patients who
return a written  informed consent are included in our
study.
Recruitment
We have chosen for a phased introduction of our study in
3 different GP out-of-hour services (weekdays from 5 pm-
8 am and weekends). Participating centers are notified of
the study progress by a monthly overview of the number
of participants and a 2-monthly newsletter with back-
ground information on the study, frequently asked ques-
tions and tips and tricks, for instance on how to draw the
required amount of capillary blood. We anticipate includ-
ing 300 patients within 36 months.
Preliminary Results
In March 2006 we started enrollment of patients. In Sep-
tember 2007, 172 patients were included; i.e. monthly
enrollment of about 12 patients. Conclusion of enroll-
ment is anticipated before the summer of 2008. Baseline
characteristics of the first participants are summarized in
Table 1.
Discussion
The presentation of the design of our study provides the
reader the opportunity to get informed about our study in
an early stage. Moreover, publishing the design of a study
independently of its results allows for a reflection on the
design of a study. It helps to reduce publication bias and
unacknowledged alterations in the study aims, the study
design or data-analysis during its conduct. Finally, this
article can be seen as an announcement of upcoming
study results that may have an impact on the guidelines
on acute coronary syndrome currently used in primary
care.
Our study on H-FABP as a new cardiac biomarker is note-
worthy as patients are recruited outside a hospital setting.BMC Cardiovascular Disorders 2008, 8:8 http://www.biomedcentral.com/1471-2261/8/8
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The, few, previous studies on H-FABP have been per-
formed in the emergency room or by ambulance person-
nel [17-23], representing an entirely different domain of
patients than those seen by the GP. This is also illustrated
by the difference in prevalence of AMI in these popula-
tions. Hospital-based studies reported a prevalence of
AMI around or above 50% in those suspected of AMI [17-
21,24], with the exception of one study that reported a
prevalence of 16% [22]. Studies performed in primary
care observed prevalences as low as 5 or 8% [13,25]. By
definition this difference in prevalence has an important
impact on the added diagnostic value of the novel rapid
bedside test.
Many (earlier) diagnostic studies focus on the perform-
ance of a single test, ignoring the information obtained
from history taking and physical examination. Based on
symptoms and signs however, the likelihood of ACS may
increase or decrease, thereby potentially altering the
added value of the test. Moreover, single test research is
not according to clinical practice, where a diagnosis is
established after multiple tests performed in a hierarchical
way, starting with simple, non-invasive and inexpensive
tests, such as signs and symptoms [26]. Therefore a clini-
cal score based on history and physical examination is
included in our diagnostic model and the added value of
the H-FABP bedside test will be calculated.
Previous studies with H-FABP in the hospital-setting
showed the potential value of this novel cardiac biomar-
ker in assessing patients suspected of ACS. Since GPs are
confronted with patients suspected of an acute coronary
syndrome at a very early stage, mostly without the availa-
bility of an ECG, the impact of a novel cardiac biomarker
on the diagnostic assessment is potentially much higher
in general practice than in the emergency room. To answer
the question whether H-FABP has (additional) diagnostic
value in the diagnosis of ACS in the primary care setting,
the test needs to be studied before its introduction in that
specific setting.
Application of an early biomarker potentially reduces
diagnostic uncertainty in patients suspected of an ACS.
On the one hand this may lead to a reduction of unneces-
sary hospital referrals, patient burden, hospital work load
and health care costs. On the other hand, a diagnosis of
ACS can be established much earlier than with troponin
which may result in earlier initiation of treatment, includ-
ing revascularization interventions.
To our knowledge, our study is the first to assess the
(added) diagnostic value of H-FABP in patients with chest
pain or other complaints suggestive of ACS in primary
care.
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